Danaher (DHR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Mar, 2026Executive summary
Annual meeting scheduled for May 5, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by May 4, 2026.
Voting matters and shareholder proposals
Election of eleven directors to serve until the 2027 annual meeting.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote to approve named executive officer compensation (say-on-pay).
Approval of the Amended and Restated Omnibus Incentive Plan.
Provision to address any other business that may arise at the meeting.
Board of directors and corporate governance
Eleven nominees listed for election, including Rainer M. Blair, Feroz Dewan, Linda Filler, and others.
Board recommends voting in favor of all director nominees.
Latest events from Danaher
- 2026 proxy covers director elections, pay, auditor, incentive plan, and major acquisition.DHR
Proxy filing25 Mar 2026 - 2026 outlook targets strong growth, margin expansion, and innovation, driven by bioprocessing and diagnostics.DHR
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - 2025 ended with strong growth and cash flow; 2026 guidance targets higher revenue and EPS.DHR
Q4 20253 Feb 2026 - Q2 2024 revenue fell 3%, margin improved, and $4.6B was spent on share repurchases.DHR
Q2 20243 Feb 2026 - High single-digit growth and margin expansion driven by innovation and global diagnostics leadership.DHR
Investor Day 202422 Jan 2026 - Q3 revenue up 3%, adjusted EPS $1.71, but core sales and net earnings face headwinds.DHR
Q3 202419 Jan 2026 - Strong Q4 2025 results and innovation drive high-single digit long-term growth.DHR
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Strong Q3 results, diagnostics innovation, and bioprocessing recovery drive positive outlook.DHR
7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026 - Strong Q4 results, high recurring revenue, and innovation drive long-term growth outlook.DHR
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026